Fortrea, FTRE and NASDAQ
Discover how FTRE's $7.7B backlog, CRO market growth, and focus on high-margin areas ensure long-term growth, efficiency, and ...
Fortrea (NASDAQ:FTRE – Get Free Report) had its target price decreased by analysts at The Goldman Sachs Group from $22.00 to ...
StockStory.org on MSN3d
Why Fortrea (FTRE) Shares Are Plunging TodayShares of clinical research company Fortrea Holdings (NASDAQ:FTRE) fell 18.5% in the pre-market session after the company ...
BofA lowered the firm’s price target on Fortrea (FTRE) to $10 from $17 and keeps an Underperform rating on the shares after a Q4 miss and FY25 ...
Fortrea (NASDAQ:FTRE – Get Free Report) had its price objective lowered by investment analysts at Barclays from $25.00 to $12 ...
A Durham company with a slumping stock is implementing changes to its board after reaching a deal with an activist investor.
Barclays lowered the firm’s price target on Fortrea (FTRE) to $12 from $25 and keeps an Equal Weight rating on the shares.Discover the Best ...
Shares of Fortrea Holdings sank to a new low after the company said it expects revenue to drop this year. The stock fell 31% to a new all-time low of $9.55 in the first half of the trading day. The ...
In a recent interview with Fierce Biotech's Chris Hayden, Fortrea's Chief Technology and Data Officer Alaric Jackson ...
For the three months and full-year ended December 31, 2024, from continuing operations:Revenues of $697.0 million for the fourth quarter, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback